Replies to post #86541 on Biotech Values

[akasidney86]

I find it interesting that the two companies estimates of the terms of the royalty agreement under multiple approval scenario are so different -- 12% and 20%. Yet they both come up with almost the same share valuation target... but curioser still, the 12% royalty gets a higher target ($17) than the 20% ($15).

[zipjet]

Thanks for the MNTA reports.

Jim

[ghmm]

THanks as well for posting the repots.

I noticed the Canaccord report

Momenta intends to start a large, relatively expensive Phase 2b trial of
M118 in ACS in 2010, which could significantly increase R&D spend if the program is not
partnered.

I am pretty sure I heard (on the Lazard Call?) that they will NOT start this until they find a partner.